AssetMark Inc
CTXR icon

AssetMark Inc’s Citius Pharmaceuticals CTXR Stock Holding History

AssetMark Inc’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335 Buy
+372
New +$300 ﹤0.01% 3251

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AssetMark Inc's CTXR Position: Q1 2026 in Review

AssetMark Inc opened a new position in Citius Pharmaceuticals (CTXR) in Q1 2026: 372 shares worth $335. The stake represents ﹤0.01% of the portfolio and ranks #3251 among its holdings.

38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • AssetMark Inc held 372 shares of Citius Pharmaceuticals worth $335 as of Q1 2026.
  • Citius Pharmaceuticals was a new AssetMark Inc position in Q1 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #3251 holding.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.